AbCellera Biologics (ABCL) Competitors $3.23 +0.21 (+6.95%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$3.24 +0.00 (+0.15%) As of 05:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL vs. LYEL, APLS, OGN, HCM, IBRX, AMRX, XENE, MIRM, ARWR, and AAPGShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Lyell Immunopharma (LYEL), Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), HUTCHMED (HCM), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. Its Competitors Lyell Immunopharma Apellis Pharmaceuticals Organon & Co. HUTCHMED ImmunityBio Amneal Pharmaceuticals Xenon Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals Ascentage Pharma Group International Lyell Immunopharma (NASDAQ:LYEL) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Is LYEL or ABCL more profitable? AbCellera Biologics has a net margin of -533.32% compared to Lyell Immunopharma's net margin of -323,792.09%. AbCellera Biologics' return on equity of -15.73% beat Lyell Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-323,792.09% -34.64% -30.02% AbCellera Biologics -533.32%-15.73%-12.22% Do analysts prefer LYEL or ABCL? Lyell Immunopharma presently has a consensus target price of $20.00, suggesting a potential upside of 112.54%. AbCellera Biologics has a consensus target price of $8.33, suggesting a potential upside of 158.00%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk and volatility, LYEL or ABCL? Lyell Immunopharma has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Do insiders and institutionals hold more shares of LYEL or ABCL? 66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in LYEL or ABCL? AbCellera Biologics received 43 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 76.00% of users gave AbCellera Biologics an outperform vote while only 43.75% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformLyell ImmunopharmaOutperform Votes1443.75% Underperform Votes1856.25% AbCellera BiologicsOutperform Votes5776.00% Underperform Votes1824.00% Does the media refer more to LYEL or ABCL? In the previous week, Lyell Immunopharma had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 7 mentions for Lyell Immunopharma and 6 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.72 beat Lyell Immunopharma's score of 0.66 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, LYEL or ABCL? AbCellera Biologics has higher revenue and earnings than Lyell Immunopharma. AbCellera Biologics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$65K2,143.74-$234.63M-$25.00-0.38AbCellera Biologics$23.11M41.70-$146.40M-$0.56-5.77 SummaryAbCellera Biologics beats Lyell Immunopharma on 15 of the 18 factors compared between the two stocks. Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$963.91M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-5.298.7827.1120.06Price / Sales41.70255.64409.88157.10Price / CashN/A65.8538.2534.64Price / Book0.816.557.064.70Net Income-$146.40M$143.93M$3.23B$247.88M7 Day Performance36.29%3.97%2.88%2.66%1 Month Performance56.80%11.32%9.04%6.40%1 Year Performance-5.56%4.20%31.40%14.07% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.487 of 5 stars$3.23+7.0%$8.33+158.0%-5.8%$963.91M$23.11M-5.29500Options VolumeGap UpHigh Trading VolumeLYELLyell Immunopharma3.1508 of 5 stars$8.22-5.9%$1.00-87.8%-81.3%$2.43B$65K-10.40270Short Interest ↓Gap DownHigh Trading VolumeAPLSApellis Pharmaceuticals4.7675 of 5 stars$19.14+13.1%$40.05+109.3%-54.9%$2.41B$775.84M-9.43770Analyst RevisionHigh Trading VolumeOGNOrganon & Co.4.7934 of 5 stars$9.22-0.1%$18.00+95.3%-50.1%$2.40B$6.29B2.7710,000Trending NewsHCMHUTCHMED1.5085 of 5 stars$13.60-2.1%$19.00+39.7%-4.2%$2.37B$630.20M0.001,760Upcoming EarningsIBRXImmunityBio2.3442 of 5 stars$2.67+0.4%$12.25+358.8%-45.6%$2.36B$31.22M-2.90590High Trading VolumeAMRXAmneal Pharmaceuticals3.7362 of 5 stars$7.42+1.4%$11.50+55.0%+10.7%$2.33B$2.83B-10.917,600Positive NewsXENEXenon Pharmaceuticals3.6872 of 5 stars$30.07+4.2%$54.82+82.3%-15.0%$2.31B$7.50M-10.66210Options VolumeAnalyst RevisionMIRMMirum Pharmaceuticals3.8483 of 5 stars$45.97+3.4%$60.73+32.1%+85.0%$2.28B$379.25M-22.76140Analyst RevisionARWRArrowhead Pharmaceuticals3.6102 of 5 stars$16.40+2.1%$42.13+156.9%-32.1%$2.26B$545.21M-3.17400Analyst RevisionAAPGAscentage Pharma Group InternationalN/A$25.22+3.4%N/AN/A$2.20B$980.65M0.00600 Related Companies and Tools Related Companies Lyell Immunopharma Competitors Apellis Pharmaceuticals Competitors Organon & Co. Competitors HUTCHMED Competitors ImmunityBio Competitors Amneal Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Ascentage Pharma Group International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABCL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABCL Stock Free ABCL Stock Alerts